Oncodesign Precision Medicine S.A Logo

Oncodesign Precision Medicine S.A

ALOPM | Euronext Access Plus

Overview

Corporate Details

ISIN(s):
FR001400CM63
LEI:
969500ZDX1IY47LDL876
Country:
France
Address:
18 RUE JEAN MAZEN, 21000 DIJON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine. Its core mission is to discover and develop innovative therapeutic and diagnostic solutions for cancers that exhibit therapeutic resistance and metastasis. The company employs a patient-centric, translational approach, leveraging proprietary technology platforms to identify effective treatments and address the challenges of cancer evolution. OPM focuses on advancing its pipeline of drug candidates to provide new options for patients with resistant and metastatic cancers.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Oncodesign Precision Medicine S.A. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-11 18:00
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 466.5 KB
2025-05-06 18:00
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 216.8 KB
2025-04-17 18:00
Capital/Financing Update
Inside Information / Other news releases
English 341.8 KB
2025-04-17 18:00
Capital/Financing Update
Informations privilégiées / Autres communiqués
French 331.1 KB
2025-04-03 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 364.7 KB
2025-04-03 18:00
Earnings Release
Inside Information / News release on accounts, results
English 379.5 KB
2025-03-24 18:11
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 540.6 KB
2025-03-24 18:11
Legal Proceedings Report
Inside Information / Other news releases
English 629.3 KB
2025-03-04 17:45
Board/Management Information
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
French 293.7 KB
2025-03-04 17:45
Board/Management Information
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Dire…
English 287.9 KB
2025-01-08 18:00
Capital/Financing Update
Informations privilégiées / Autres communiqués
French 604.4 KB
2024-12-20 08:00
Regulatory News Service
Inside Information / Other news releases
English 296.9 KB
2024-12-20 08:00
M&A Activity
Informations privilégiées / Autres communiqués
French 284.3 KB
2024-10-22 18:00
Regulatory News Service
Inside Information / Other news releases
English 310.0 KB
2024-10-22 18:00
Regulatory News Service
Informations privilégiées / Autres communiqués
French 312.5 KB

Automate Your Workflow. Get a real-time feed of all Oncodesign Precision Medicine S.A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oncodesign Precision Medicine S.A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA